BioTuesdays

Maxim reduces PTs in challenging biotech market

Maxim Group analyst Jason McCarthy, Ph.D., reduced price targets for 13 stocks in his coverage universe, citing macroeconomic winds and a significant decline in stock prices, particularly for small-cap biotech stocks...

Pliant Therapeutics

Cantor starts Pliant Therapeutics at OW; PT $12

Cantor Fitzgerald launched coverage of Pliant Therapeutics (NASDAQ:PLRX) with an “overweight” rating and 12-month price target of $12. The stock closed at $4.93 on May 24. Pliant is developing novel therapies for...

Know Labs

Know Labs adds CFO, CPO to leadership team

Peter Conley and Steven Kent joined the leadership team at Know Labs (OTCQB:KNWN) as chief financial officer and chief product officer, respectively. Mr. Conley also takes on the position of SVP, intellectual property...

Cantor starts Lyra Therapeutics at OW; PT $15

Cantor Fitzgerald initiated coverage of Lyra Therapeutics (NASDAQ:LYRA) with an “overweight” rating and price target of $15. The stock closed at $6.07 on May 23. Lyra is a clinical-stage company developing medicines...

MindMed

MindMed names Schond Greenway as CFO

Schond Greenway Mind Medicine (NASDAQ:MNMD; NEO:MMED) appointed Schond Greenway as CFO. He comes to MindMed with more than 20 years of experience in investment banking, finance and corporate advisory, and investment...

HilleVax

Analysts start HilleVax at buy, outperform

Analysts for Stifel and SVB Securities initiated coverage of HilleVax (NASDAQ:HLVX) with “buy” and “outperform” ratings, and price targets of $34 and $30, respectively. The stock closed at $9.50 on May 23. The company’s...

Profound Medical

Profound Medical insiders add to holdings 

Profound Medical (NASDAQ:PROF; TSX:PRN) independent lead director, Brian Ellacott, and chairman and CEO, Arun Menawat, purchased additional shares of Profound on Nasdaq after the company’s 2022 first quarter blackout...